Podcasts about aaic

Welcome to the sixth season of the Dementia Researcher X ISTAART PIA Relay Podcast. This series features interviews with ISTAART PIA committee members talking about their research, the research landscape of their fields, and the work of the ISTAART Professional Interest Areas (PIA) they represent. As we build up to the Alzheimer's Association International Conference in Toronto, join us for daily episodes that showcase the remarkable work being done in various research fields. -- In this Relay Podcast episode, Dr Colin Groot interviews Dr Marta Del Campo, Head Fluid Biomarker Facility; Ramón y Cajal Research fellow at BarcelonaBeta Brain Research Center and chair of the ISTAART Biofluid Based Biomarkers PIA. Together, they talk about recent advances in fluid biomarkers in dementia research, and explore the growing role of plasma biomarkers, integration with clinical trials, challenges with reproducibility and diversity, and the promise of proteomics and AI. Marta also reflects on the work of ISTAART, their plans for AAIC, the value of publishing negative findings, and why ISTAART offers vital opportunities for early career researchers. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- Find more information on our guests, and a full transcript of this podcast on our website at: http://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Welcome to the sixth season of the Dementia Researcher X ISTAART PIA Relay Podcast. This series features interviews with ISTAART PIA committee members talking about their research, the research landscape of their fields, and the work of the ISTAART Professional Interest Areas (PIA) they represent. As we build up to the Alzheimer's Association International Conference in Toronto, join us for daily episodes that showcase the remarkable work being done in various research fields. -- In this episode, Professor Owen Carmichael talks with Dr Shana Stites, Assistant Professor at University of Pennsylvania and Chair of the ISTAART Diversity and Disparities PIA. In this discussion they explore the importance of inclusive participation in dementia research, the challenges of equitable access to research and care, and the shift toward more community-engaged approaches. The conversation highlights barriers like limited access to healthcare, the ethics of stipends, and the value of transparency, reciprocity, and representation in Alzheimer's disease and related research. They also talk about the wider work and aims of the PIA and what they have planned for the upcoming AAIC. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- Find more information on our guests, and a full transcript of this podcast on our website at: http://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Welcome to the sixth season of the Dementia Researcher X ISTAART PIA Relay Podcast. This series features interviews with ISTAART PIA committee members talking about their research, the research landscape of their fields, and the work of the ISTAART Professional Interest Areas (PIA) they represent. As we build up to the Alzheimer's Association International Conference in Toronto, join us for daily episodes that showcase the remarkable work being done in various research fields. -- In this episode, Professor Natalie Phillips interviews Professor Owen Carmichael, Director of Biomedical Imaging at Pennington Biomedical Research Center and incoming chair of the iSTAART Nutrition, Metabolism, and Dementia PIA. Owen shares his journey from computer science to neuroscience, and how his imaging work investigates how diet and metabolism shape dementia risk. They explore the promise of precision nutrition, the challenges of studying lifelong dietary exposure, and the vital role of olfaction and sensory health in nutrition. The episode also discusses the importance of inclusive research and lifelong data to understand and prevent cognitive decline. The show rounds-up the PIAs upcoming work at the AAIC, and the work of the PIA. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- Find more information on our guests, and a full transcript of this podcast on our website at: http://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Welcome to the sixth season of the Dementia Researcher X ISTAART PIA Relay Podcast. This series features interviews with ISTAART PIA committee members talking about their research, the research landscape of their fields, and the work of the ISTAART Professional Interest Areas (PIA) they represent. As we build up to the Alzheimer's Association International Conference in Toronto, join us for daily episodes that showcase the remarkable work being done in various research fields. -- In this episode, Dr Marta del Campo interviews Natalie Phillips, Chair of the Sensory Health and Cognition PIA and Professor of Psychology at Concordia University. Together, they discuss the role of hearing, vision, and olfaction in cognitive ageing and dementia risk. They explore mechanisms behind these links, from cognitive load to social isolation, and discuss emerging biomarker research, challenges in clinical implementation, and how this new ISTAART PIA is fostering interdisciplinary collaboration. The episode also previews upcoming activities at AAIC and highlights opportunities for early career researchers to get involved. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- Find more information on our guests, and a full transcript of this podcast on our website at: http://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Welcome to the sixth season of the Dementia Researcher X ISTAART PIA Relay Podcast. This series features interviews with ISTAART PIA committee members talking about their research, the research landscape of their fields, and the work of the ISTAART Professional Interest Areas (PIA) they represent. As we build up to the Alzheimer's Association International Conference in Toronto, join us for daily episodes that showcase the remarkable work being done in various research fields. -- In this Relay Podcast episode, Dr Colin Groot interviews Dr Marta Del Campo, Head Fluid Biomarker Facility; Ramón y Cajal Research fellow at BarcelonaBeta Brain Research Center and chair of the ISTAART Biofluid Based Biomarkers PIA. Together, they talk about recent advances in fluid biomarkers in dementia research, and explore the growing role of plasma biomarkers, integration with clinical trials, challenges with reproducibility and diversity, and the promise of proteomics and AI. Marta also reflects on the work of ISTAART, their plans for AAIC, the value of publishing negative findings, and why ISTAART offers vital opportunities for early career researchers. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- Find more information on our guests, and a full transcript of this podcast on our website at: http://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Adam Smith narrates his blog written for Dementia Researcher. In this guest blog, Adam offers a view of what to expect from the Alzheimer's Association International Conference (AAIC) 2025. Drawing on past experiences, he outlines why this global event matters, what makes it unique, and how first-timers can make the most of it without becoming overwhelmed. From orientation lounges to poster sessions and career development opportunities, Adam provides reassurance and practical advice for navigating the intensity of a week at one of the biggest dementia research conferences in the world – whether you're attending in person or online. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-aaic-2025-big-busy-and-worth-it/ -- Adam Smith was born in the north, a long time ago. He wanted to write books, but ended up working in the NHS, and at the Department of Health.  He is now Programme Director in the Office of the NIHR National Director for Dementia Research (which probably sounds more important than it is) at University College London. He has led a number of initiatives to improve dementia research (including this website, Join Dementia Research & ENRICH), as well as pursuing his own research interests. In his spare time, he grows vegetables, builds Lego & spends most of his time drinking too much coffee and squeezing technology into his house. -- Enjoy listening? We're always looking for new bloggers, drop us a line. http://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social

In the span of a few days, two houses of worship in Minneapolis are facing threats and vandalism.Minneapolis Police are currently investigating the defacing of Temple Israel, a synagogue in Minneapolis. On Monday, a suspect spray-painted swastikas on the doors and pillar of the building. On Friday, Abubakar As-saddique Islamic Center, or AAIC in Minneapolis received an online threat, threatening violence to members of worship at the mosque. Minneapolis police determined the threat to be unfounded, but it still contributed to fear and concern in the Islamic community. Rabbi Marcia Zimmerman, the senior rabbi at Temple Israel and Osman Ahmed, Director of Advocacy with Minnesota's Chapter of the Council on American-Islamic Relations joined Minnesota Now host Nina Moini to talk about their response to the threats.

What's ready for prime time and what's in the pipeline in Alzheimer's disease (AD) diagnosis and care? View conference highlights to find out. Credit available for this activity expires: 8/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001535?ecd=bdc_podcast_libsyn_mscpedu

Sebastian Palmqvist, MD, PhD, and Wiesje van der Flier, PhD, cochairs of the 2024 Alzheimer's Association International Conference, speak with JAMA Medical News Lead Senior Staff Writer Rita Rubin, MA, about highlights from the annual meeting, including a blood test for Alzheimer disease, repurposing of a GLP-1 receptor agonist, and the possible brain risk from inhaling wildfire smoke. Related Content: A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke—Highlights From the AAIC

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer's Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN's ongoing efforts to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell's latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio's recent Phase 2/3 Alzheimer's study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio's strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson's and Alzheimer's diseases. “Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer's patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer's research, underscores the importance of our work and the promise it holds for patients.” Join IBN's Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio's recent achievements, the next steps for buntanetap, and the company's future goals. To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com. The latest installment of The Bell2Bell Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN's achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer's Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN's ongoing efforts to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell's latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio's recent Phase 2/3 Alzheimer's study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio's strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson's and Alzheimer's diseases. “Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer's patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer's research, underscores the importance of our work and the promise it holds for patients.” Join IBN's Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio's recent achievements, the next steps for buntanetap, and the company's future goals. To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com. The latest installment of The Bell2Bell Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN's achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Join StartUp Health NOW for a powerful episode recorded live at the Alzheimer's Association International Conference (AAIC)! We explore the exciting inflection point in Alzheimer's research fueled by AI and machine learning. Hear directly from passionate founders in the StartUp Health Alzheimer's Moonshot Community: Catherine Bornbaum, PhD, CBO at RetiSpec, fresh off the company's $10M Series A, unveils a groundbreaking AI-powered device that analyzes the retina for insights into brain health. Ken Mariash, CEO of Sinaptica Therapeutics, discusses using AI and neuromodulation to potentially slow Alzheimer's and strengthen brain function in healthy individuals. Discover: How AI is unlocking a multi-modal understanding of the brain The potential for revolutionizing treatment for all brain conditions The cutting-edge technologies shaping the future of Alzheimer's research This episode is a must-listen for anyone passionate about brain health and the fight against Alzheimer's! Innovating in Alzheimer's disease? Learn how you can join our Alzheimer's Moonshot. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox. Innovators: Health Transformer University fuels your health moonshot Funders: Become a Health Moonshot Champion

In this podcast we share a few selected highlights from the fourth day of the Alzheimer's Association International Conference (AAIC) taking place in Philadelphia and Online, 28th July to 1st August. Dr Amanda Heslegrave, Principle Research Fellow at University College London, hosts the show with special guests: Dr Darina Petrovsky, Assistant Professor at Duke University Dr Emily Ho, Assistant Professor at Northwestern University Meenakshi Menon, ISTAART Ambassador and incoming PhD student in Cognitive Sciences at Georgia State University The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Main plenary talks from the day included Tara Spires-Jones presenting on 'Synaptic Oligomeric Tau In Alzheimer's Disease — A Potential Culprit In The Spread Of Tau Pathology Through The Brain ', Ricardo F. Allegri on 'Dementia Research In Low- And Middle-Income Countries: Initiatives That Seize Opportunities, Overcome Challenges And Build Capacity'. #AAIC24 -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this podcast we share a few selected highlights from the last day of the Alzheimer's Association International Conference (AAIC) taking place in Philadelphia and Online, 28th July to 1st August. Quang Tran, Science Communications Officer for Alzheimer's Research UK, guest hosts the show with expert panelists: Dr Shea Andrews, Assistant Professor at University of California San Francisco working on Genetic Epidemiology of Alzheimer's disease. Dr Joe Butler, NIHR ARC Research Fellow at University of Sunderland, interested in using techniques and paradigms from experimental psychology to learn about brain health. Roberto A. Guzmán Hernández, ISTAART Ambassador, Graduate Research Assistant and PhD Student at Temple University working on the effects of aggregated tau on endothelial and cerebrovascular dysfunction -- The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Main plenary talks from the day included Michael Weiner 'ADNI: Two Decades Of Impact And The Path Forward', Reisa Sperling ' Preclinical Alzheimer's Disease'. Today was also the first AAIC For ALL, a new format with talks for professional from Jeffrey Cummings on the Therapeutic Landscape, Heather Whitson on The Role Of Blood Tests In Diagnosis And Treatment, Clifford Jack on Criteria For Diagnosis And Staging, Monica Rivera-Mindt on Health Equity And Risk Reduction and Katherine Possin on Dementia Care. Talks for a lay audience from Edward B. Lee on Brain Donation: The Gift Of Knowledge, Hussein Zalzale on The Many Faces Of Alzheimer's Dementia, Subtypes And Unique Features, Dawn Mechanic-Hamilton on How Can We Improve Cognitive Testing? The Answer May Be In The Palm Of Your Hand, Cerise Elliot on Building Inclusive Alzheimer's And Related Dementias Research Studies, Wiesje van der Flier on 'Risk Reduction', Jonathan Schott on 'Diagnosis And Treatment', Nancy Hodgson on 'Dementia Care', Ozioma Okonkwo on 'Health Equity'. #AAIC24 -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Second-quarter earnings season continues with Big Pharma beating Wall Street expectations, the author of an encrypted email sent to BioSpace has a proposal for Moderna and Merck, Roche and Viking seek quicker entry to the obesity market, and AAIC is in full swing. As July comes to a close, biopharma second-quarter earnings continue to roll in with Pfizer, Merck, AbbVie, AstraZeneca and many more reporting. So far, everything is coming up roses with most major companies beating Wall Street expectations. But every rose has its thorn and for biopharma executives this has long been drug price negotiations under the Inflation Reduction Act. Recently, however, drugmakers have expressed confidence that the IRA will not greatly impact their bottom lines. Speaking of bottom lines, in an anonymous email sent to the CFOs of Merck and Moderna and shared with BioSpace, a shareholder made the case that Merck should buy Moderna out of its 50/50 partnership involving Keytruda and their shared investigational personalized cancer vaccine. Meanwhile, M&A activity picked up in the second quarter of 2024 with nearly $18 billion changing hands, according to J.P. Morgan. Q3 has been no stranger to deals so far, either, with Boehringer Ingelheim acquiring Nerio Therapeutics for up to $1.3 billion to boost its immuno-oncology pipeline, and GSK and Flagship Pioneering striking a potential $7B deal to develop a portfolio of novel vaccines and medicines starting with immunology and respiratory treatments. Pfizer raised its full-year outlook after reporting positive Q2 results and announced layoffs this week at two North Carolina sites, with a total of 210 workers losing their jobs. Cuts at the Sanford, N.C. gene therapy manufacturing site come on the heels of Pfizer's Duchenne muscular dystrophy gene therapy failed a Phase III trial. On the obesity front, both Viking Therapeutics and Roche indicated that they will seek entry to the market more quickly than originally anticipated, and the FDA issued a warning on Monday about possible safety risks associated with compounded versions of Novo Nordisk's semaglutide. And the Alzheimer's Association International Conference (AAIC) this week revealed some interesting nuggets, including long-term data regarding Eisai and Biogen's Leqembi, and a small Phase IIb study showing that Novo's GLP-1 liraglutide slowed cognitive decline in Alzheimer's patients by up to 18%.

In this podcast we share a few selected highlights from the third day of the Alzheimer's Association International Conference (AAIC) taking place in Philadelphia and Online, 28th July to 1st August. Caitlyn Fastenau,  PhD Candidate at University of Texas Health San Antonio, hosts the show with special guests: Balogun Wasiu, Postdoctoral Associate at University of Pittsburgh Jessica Caldwell, Director, Women's Alzheimer's Movement Prevention and Research Center, Cleveland Clinic Sophia Krix, PhD Student at University of Bonn, working on the ADIS Project The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Main plenary talks from the day included Suvarna Alladi 'Bilingualism And Dementia: Implications For Brain Health And Policy Development', Clive Ballard on 'Psychosis In Alzheimer's Disease'. #AAIC24 -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this podcast we share a few selected highlights from the first two days of the Alzheimer's Association International Conference (AAIC) taking place in Philadelphia and Online, 28th July to 1st August. Dr Francesca Farina hosts the show with special guests: Dr Annalise Rahman-Filipiak, Assistant Professor, Clinical Neuropsychologist at University of Michigan Dr Tamlyn Watermeyer, NIHR / Alzheimer's Society Dem Comm Fellow at Northumbria University and University of Edinburgh working on cognition and brain health. Dr Merci Best, Research Fellow at the University of Michigan's Paulson Lab, studying the molecular mechanisms of tau-mediated neurodegeneration The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Main plenary talks from the day included Edward B. Lee presenting 'Neuropathology In A Multidisciplinary Age', Timothy Miller on 'Antisense Oligonucleotide Therapeutics For Neurodegenerative Diseases', Henne Holstege delivering a talk titled 'From Longevity To Vulnerability: Genomic Pathways Underlying Cognitive Health In Centenarians And Neurodegenerative Disease'. #AAIC24 @alzassociation -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Join us for another episode of the ISTAART Relay Podcast brought to you by Dementia Researcher. We're releasing one of these shows each week in the build up to the AAIC, which this year starts on the 28th July. In this episode, Dr Diana Karamacoska takes over the hot seat to interview Dr Keir Yong, a Senior Research Fellow at University College London, about the intricacies of Atypical Alzheimer's Disease, and the work of the Atypical Alzheimer's Disease PIA. Discover how posterior cortical atrophy (PCA), a less common variant of Alzheimer's, impacts patients' lives and the innovative research aiming to improve diagnosis and treatment. Get insights into the diagnostic challenges, the role of biomarkers, and the essential interdisciplinary collaborations driving advancements in this field. Don't miss this deep dive into Keir's work, hot topics in the field, and how their PIA is making a difference. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org. Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- You can also enjoy this show as a video on our YouTube Channel at: https://youtu.be/53wt10WyURI -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this episode of the ISTAART Relay Podcast, Dr Jessica Caldwell, a neuropsychologist and director at the Cleveland Clinic, interviews Dr Ece Bayram, the newly appointed assistant professor and incoming communications chair for the ISTAART Lewy Body Dementias PIA. They explore Ece's research on sex differences in genetics and environmental risk factors for Lewy body dementia. Ece shares insights into her innovative projects, the work of their PIA, plans for the upcoming AAIC and the significance of understanding sex and gender differences in neurodegenerative diseases, and the importance of designing research with community involvement. They also discuss the challenges of conducting studies in diverse populations and the need for global collaboration. Tune in to hear about the exciting developments in Lewy body dementia research and the impact of community-driven studies on advancing the field. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org You can also enjoy this show as a video on our YouTube Channel at: https://youtu.be/psSB1wOGSxA -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Welcome to the fifth season of the ISTAART PIA Relay Podcast, brought to you by Dementia Researcher. In this six-part series, members of ISTAART professional interest areas (PIAs) take turns interviewing their colleagues about the latest research in Alzheimer's disease and other dementias. This episode features a Caitlyn Fastenau, a PhD candidate from the University of Texas Health Science Centre interviewing Dr Jessica Caldwell, a neuropsychologist and director of the Women's Alzheimer's Movement Prevention and Research Centre at Cleveland Clinic. Dr Caldwell discusses her pioneering work at the world's only clinic designed specifically for women to reduce their Alzheimer's risk, focusing on sex and gender differences in the disease. She highlights the critical role of menopause, stress, and hormonal changes in Alzheimer's risk and shares insights into the importance of diverse research populations and the unique challenges faced by women caregivers. Tune-in as explore hot topics of sex and gender differences in Alzheimer's research, including the impact of menopause, the need for gender-diverse studies, and the initiatives of the ISTAART Sex and Gender PIA and what they have planned for AAIC. Whether you're a researcher, clinician, or someone affected by Alzheimer's, this episode offers valuable perspectives on the intersections of gender, health, and dementia. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org You can also enjoy this show as a video on our YouTube Channel at: https://youtu.be/E0NWtCyJtzI -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Welcome to the fifth season of the ISTAART PIA Relay Podcast, brought to you by Dementia Researcher. This series features members of ISTAART, engaging in insightful interviews about groundbreaking dementia research, and the work of the ISTAART Professional Interest Areas (PIA) they represent. As we build up to the Alzheimer's Association International Conference in Philadelphia, join us for daily episodes that showcase the remarkable work being done in various research fields. -- In this episode, Professor Arlene Astell interviews Caitlyn Fastenau, a PhD candidate in Integrated Biomedical Sciences focusing on the Biology of Ageing. Caitlyn shares her journey into dementia research, driven by personal experiences and a passion for understanding neurodegenerative diseases. Her research explores the role of immune cells, particularly microglia, in Alzheimer's disease, using advanced techniques like single-cell RNA sequencing. Caitlyn discusses the her work, the importance of diversity in research, highlighting efforts to include underrepresented communities in dementia studies. She also talks about the significance of translational research and the potential non-pharmacological interventions that could reduce the risk of neurodegenerative diseases. Tune in to learn more about the Immunity and Neurodegeneration PIA, what they have planned for AAIC and the latest hot topics in the field, and the collaborative environment that ISTAART provides for researchers at all levels. PS. Don't miss Caitlyn's presentation at the AAIC and her insights on leveraging student engagement in scientific societies. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- You can also enjoy this show as a video on our YouTube Channel at: https://youtu.be/dddOpDsuwlM -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Adam Smith chats with Dr Claire Sexton, Senior Director, Scientific Programs and Outreach from the Alzheimer's Association. Discussing this year's Alzheimer's Association International Conference (AAIC) 28th July to 1st August (+preconference on the 25th – 27th). -- Taking place in-person in Philadelphia and online - the world's leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer's disease. In this exciting edition, we will be giving you an exclusive sneak peek into one of the most highly anticipated events in dementia research conference calendar (also a world first exclusive on the location for 2025). Join us as we explore into how you can attend, the scientific programme, extra events and just what the AAIC will deliver this year. With leading experts, visionary thinkers, and research pioneers gathering under one roof, this conference promises to not only showcase groundbreaking discoveries, but also be a place where you will get careers support, and unrivalled networking opportunities. -- To book your place visit – http://www.aaic.alz.org AAIC for ALL - https://www.alz.org/aaic-for-all/overview.asp Dr Helena Gellersen's blog on getting the most out of AAIC: https://www.dementiaresearcher.nihr.ac.uk/blog-ultimate-guide-to-making-the-most-of-the-aaic -- Students worldwide and researchers from Low- and Middle-Income Countries are now eligible for free ISTAART Membership (and ISTAART members can attend the AAIC Online for Free) - Become a member, then register for the conference if you can't make it in-person. Join ISTAART to get a free online ticket – http://www.istaart.alz.org -- Full biographies on all our guests and a transcript can be found on our website www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you'll find a video version of this podcast with full captions on our YouTube Channel. -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

Helena Gellersen, narrates her blog written for the Dementia Researcher website. Helena shares valuable tips on making the most of academic conferences, particularly the Alzheimer's Association International Conference (AAIC). She offers practical advice on leveraging conference resources, setting goals, effective networking, and presenting research. She emphasises the importance of preparation, strategic planning, and follow-up to enhance the conference experience and foster meaningful connections, ultimately advancing one's career. Her guidance is particularly beneficial for early career researchers navigating the often overwhelming environment of large academic conferences. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-ultimate-guide-to-making-the-most-of-the-aaic/ -- Dr Helena Gellersen is a Postdoctoral Researcher at the German Center for Neurodegenerative Diseases (DZNE) and current Education Chair Trainee for the ISTAART Neuroimaging. The focus of Helena's work is on identifying preclinical signatures of Alzheimer's disease and to develop novel memory and neuroimaging markers for the early detection of Alzheimer's disease and for monitoring disease progression. @HGellersen Find out more about the Neuroimaging PIA and ISTAART at alz.org/istaart -- Enjoy listening? We're always looking for new bloggers, drop us a line. http://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher

Sára Erzsebet Zsadányi narrates her blog written for Dementia Researcher. Sara shares her thoughts on last months AAIC Neuroscience Next Conference. This hybrid event, designed to bridge local and global scientific communities, has successfully showcased emerging talent in Alzheimer's and dementia research over the past four years. Focusing on inclusivity and accessibility, the conference offers free participation and features multiple hubs worldwide, including Brazil, San Francisco, India, Ireland, Ethiopia, Serbia, and Chicago. It combines live and virtual elements to facilitate broad engagement, emphasising opportunities for early-career researchers. The event's innovative format not only promotes knowledge exchange across continents but also supports economic activities in host locations, thereby broadening the conference's impact beyond the academic sphere. To express an interest in hosting a hybrid hub in 2025, make sure to submit your application. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-a-look-inside-aaic-neuroscience-next/ -- Sára Erzsebet Zsadányi is a PhD Student at the Sant Pau Memory Unit – Neuroimaging Core and Universitat Autonoma de Barcelona. Originally from New Zealand, Sára's current work focusses on neuroimaging of small vessel disease in Down Syndrome. In previous roles she has worked on healthy brain aging and meditation, and is currently an ISTAART Ambassador. -- Enjoy listening? We're always looking for new bloggers, drop us a line. http://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher

In this podcast we learn what to expect from the upcoming AAIC Neuroscience Next Conference, a global, no-cost event that aims to support and showcase the next generation of Alzheimer's and dementia researchers and clinicians. Adam Smith, Dementia Researcher Programme Director is join by some of the people behind making it all happen. Dr Igor Fontana, Alzheimer's Association Director, Scientific Conference Programming. Dr Francesca Farina, Assistant Professor at the University of Chicago and Global Brain Health Institute at Trinity College Dublin, and Dr Kaitlin Seibert, Assistant Professor of Neurology also at University of Chicago. This unique conference works on an innovative "hybrid hub" format that connects both global and local communities. With elements being in-person and online, and full in-person from hubs in the USA, Ireland, India, Ethiopia, Brazil and Serbia. Register for the online event at: https://bit.ly/3mEhcPU Details of registration for an in-person hub are available on our website. -- Full biographies on all our guests and a transcript can be found on our website: https://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you'll find a video version of this podcast with full captions on our YouTube Channel: https://youtu.be/Q4KHRysX3E0 -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support. -- Follow us on Social Media: www.instagram.com/dementia_researcher/ www.facebook.com/Dementia.Researcher/ twitter.com/demrescommunity www.bsky.app/profile/dementiare…archer.bsky.social www.linkedin.com/company/dementia-researcher

Gavin Macgregor-Skinner is a Senior Director at ISSA – The Worldwide Cleaning Trade Association. He has more than 30 years of technical experience in responding to infectious disease outbreaks and emergency management. He is also an Associate Professor in the Department of Public Health Sciences at Penn State College of Medicine and teaches three 15-week graduate courses on Public Health. Macgregor-Skinner has appeared on CNN, Fox News, BBC and many other news outlets to share his expertise on High Consequence Pathogens.   Steven Cooper is an engineer with a technical specialty in the research and development of water-based electrostatic spray systems. He has developed innovative core technology and commercial products related to air-atomizing induction-charging (AAIC) spray systems. Mr. Cooper is an engineer, a scientist, as well as an entrepreneur. He is the co-founder of ByoPlanet/Good Salt LLC, and has been involved in establishing several other successful companies. Mr. Cooper received his undergrad and masters degrees from the University of Georgia and has been continuously involved with the UGA Applied Electrostatics Laboratory for over three decades.

The 2023 Alzheimer's Association International Conference (AAIC) in Amsterdam brought together the world's leading scientists, clinical researchers, early career investigators, caregiving researchers and more to discuss the latest findings and advancements in dementia science. Dr. Percy Griffin joins the podcast to share key highlights from the conference. He discusses the use of CRISPR technology in Alzheimer's research, the significance of defining Alzheimer's by its biology rather than its symptoms and how the field is moving toward a precision medicine approach.  Guest: Percy Griffin, PhD, director of scientific engagement, Alzheimer's Association Show Notes Learn more about the Wisconsin Alzheimer's Disease Research Center's Fall Community Conversation on our website, and watch the livestream on our YouTube page. AAIC is the world's largest forum dedicated to advancing dementia research. Find more highlights from the conference, including on-demand content that is available to watch through September 20, 2023, at 11:59 p.m. CT, on the AAIC website. Find news highlights on CRISPR technology, county-level prevalence data on Alzheimer's, the ACHIEVE study and more mentioned by Dr. Griffin on the AAIC website. Listen to our AAIC 2022 highlights episode with Dr. Griffin, mentioned at 1:15, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen. Learn more about Dr. Griffin in his bio on the Alzheimer's Association's website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

In this podcast we share a few selected highlights from the fourth day of the Alzheimer's Association International Conference (AAIC) taking place in Amsterdam and Online, 16th – 20th July. Adam Smith hosts the show with special guests Vyshnavy Balendra from Saint James School of Medicine, Chicago. Dr Helena Popovi, Family physician, educator and author of three books from the Gold Coast in Australia and Dr Iain Hartnell, Research Communications Officer from Alzheimer's Society. The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. For more information visit: https://aaic.alz.org -- You can also enjoy this show as a video podcast on our YouTube Channel. -- Find more information on our guests, and a full transcript of this podcast on our website at https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this podcast we share a few selected highlights from the third day of the Alzheimer's Association International Conference (AAIC) taking place in Amsterdam and Online, 16th – 20th July. Adam Smith hosts the show with special guests Dr Jayashree Dasgupta from GBHI Trinity College Dublin, Samita Kirve from Oxford Brookes University and Sarah Gregory from The University of Edinburgh. -- The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. For more information visit: https://aaic.alz.org -- You can also enjoy this show as a video podcast on our YouTube Channel. -- Find more information on our guests, and a full transcript of this podcast on our website at https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this podcast we share a few selected highlights from the second day of the Alzheimer's Association International Conference (AAIC) taking place in Amsterdam and Online, 16th – 20th July. Adam Smith hosts the show with special guests Sára Erzsebet Zsadányi from Universitat Autònoma de Barcelona, Dr Sonata Mačiulskytė from Klaipeda University and Dr Aoife Cosgrave from Alzheimer's Research UK. -- The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. For more information visit: https://aaic.alz.org -- You can also enjoy this show as a video podcast on our YouTube Channel. -- Find more information on our guests, and a full transcript of this podcast on our website at https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

In this podcast we share a few selected highlights from the first day of the Alzheimer's Association International Conference (AAIC) taking place in Amsterdam and Online, 16th – 20th July. Adam Smith hosts the show with special guests Dr Mizuki Morisaki from University of Bristol, Sam Keat, PhD Student in the UK Dementia Research Institute at Cardiff University and Dr Arunima Sikdar a Postdoc Research Associate from University of North Carolina. -- The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. For more information visit: https://aaic.alz.org -- You can also enjoy this show as a video podcast on our YouTube Channel. -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

With an Accelerated nod for Aduhelm (aducanumab) and now full approval for Leqembi (lecanemab) in the USA, Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) have overturned decades of failure in Alzheimer's.But at the annual meeting of the Alzheimer's Association (AAIC), it's another neurology heavyweight taking center stage, as Eli Lilly (NYSE: LLY) makes clear its intention to remain a leader in the treatment of this challenging disease.At the AAIC in Amsterdam, we're speaking with two key figures from the development program for donanemab, a candidate which could slow cognitive decline for millions of people with early Alzheimer's, while generating billions in annual revenues.Lilly is presenting full results from a key Phase III trial of its antibody, which like Leqmebi, clears aberrant proteins from the brain with the goal of combatting neurodegeneration.There are important differences between the way the two molecules work, however, and Lilly is confident its approach, which includes limited duration dosing, offers the best chance of success.The new data, which form part of a regulatory submission for approval in the USA, seem to bear this out. As with other therapies in this class, all eyes will be on safety, and Lilly hopes that “treating to clear,” and then holding off on dosing, could help avoid side effects.Like Eisai, Lilly is also interested in developing a subcutaneous treatment in future, with early data for another molecule, remternetug, showing strong potential in this regard.We discuss all of this and more, in Episode 24 of The Pharma Letter Podcast.

Adam Smith chats with Dr Claire Sexton, Senior Director, Scientific Programs and Outreach from the Alzheimer's Association. Discussing this year's Alzheimer's Association International Conference (AAIC) 16 – 20 July. -- Taking place in-person in Amsterdam and online - the world's leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer's disease. In this exciting edition, we will be giving you an exclusive sneak peek into one of the most highly anticipated events in dementia research conference calendar. Join us as we delve into how you can attend, the scientific programme, extra events and just what the AAIC will deliver this year. With leading experts, visionary thinkers, and research pioneers gathering under one roof, this conference promises to not only showcase groundbreaking discoveries, but also be a place where you will get careers support, and unrivalled networking opportunities. -- To book your place visit - https://aaic.alz.org Join ISTAART to get a free online ticket – https://istaart.alz.org -- Note: Students worldwide and researchers from Low- and Middle-Income Countries are now eligible for free ISTAART Membership (and ISTAART members can attend the AAIC Online for Free) - Become a member, then register for the conference if you can't make it in-person. Full biographies on all our guests and a transcript can be found on our website www.dementiaresearcher.nihr.ac.uk -- Register to attend the Alzheimer's Society, Alzheimer's Research UK, Dementias Platform UK and UK Dementia Research Institute Networking event: https://www.smartsurvey.co.uk/s/U2N2WG/ -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you'll find a video version of this podcast with full captions on our YouTube Channel. -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

In today's episode, Dr Chi Udeh-Momoh, Research Programme and Biomarker Lead at Imperial College London and GHBI Fellow at University California, San Francisco talks to a line-up of captivating guests as we dive into sharing insights from the AAIC Satellite Symposium 2023 – focussing on the latest research from Latin America. -- This week's guests are all currently GBHI Fellows, and highly respected researchers at their home institutions: Dr Adolfo M. García, Director, Cognitive Neuroscience Center, Universidad de San Andres / Senior Atlantic Fellow, Global Brain Health Institute, University of California, San Francisco / Associate Researcher, Universidad de Santiago de Chile. Adolfo specializes in language in neurodegenerative diseases. Dr Alison Canty, Associate Professor, & Atlantic Fellow for Equity in Brain Health at Global Brain Health Institute, Trinity College Dublin / Wicking Dementia Research and Education Centre, University of Tasmania. Alison is researching Neuroplasticity in ageing and neurodegenerative disease. Dr Jayashree Dasgupta, is a GBHI Fellow and Clinical Psychologist working on translating evidence based practices to develop services for mental well-being, active aging and dementia care in India. She is also an ethics researcher and my work involves highlighting perspectives from under-represented settings into clinical research. Michelle Moses-Eisenstein, Atlantic Fellow for Equity in Brain Health and Performing Artist at Global Brain Health Institute, University of California, San Francisco. Michelle is committed to improving the lives of people with dementia and their care partners through innovation across arts programs, grants, communications, and policy. She is a creative and empathetic problem solver motivated to achieve public health solutions and health equity through relationship building, advocacy, education, stakeholder engagement, and strategic partnerships. Dr Chi Udeh-Momoh, Research Programme and Biomarker Lead and currently GHBI Fellow. Chi was I was born in Nigeria and relocated to the UK as a teenager. She has always been fascinated by the brain - how we think, learn and remember; and how these processes can be affected in disease/ alleviated therapeutically. Chi studied Neuroscience all the way through undergrad to PhD, then did my post-doc in neuroepidemiology, her focus is now on Dementia Prevention and biomarkers. -- For more information on the event visit: https://www.alz.org/satellite-symposium/overview.asp For more information on GBHI visit: https://www.gbhi.org/events/gbhi-annual-conference-2023 -- Full biographies on all our guests and a transcript can be found on our website https://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you'll find a video version of this podcast with full captions on our YouTube Channel – https://youtu.be/zy7mKB49vuw -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

On this week's Cyber Report, sponsored by Fortress Information Security, John Cofrancesco, the founder of AAIC, an innovative company that uses AI to monitor cyber networks, discusses the threat posed by TikTok, how to mitigate the threat from such invasive apps, the looming threat from Russia as allied nations increase assistance to Ukraine, what to expect from the Biden administration's upcoming National Cyber Strategy and more with Defense & Aerospace Report Editor Vago Muradian.

AAIC Special Series Part 8: Closing out our special series spotlighting the 2022 Alzheimer's Association International Conference, Dr. Percy Griffin joins the podcast to discuss highlights from this year's event. Guest: Percy Griffin, PhD, director, scientific engagement, Alzheimer's Association Show Notes Find more highlights from the conference, including on-demand content that is available to watch through September 1, 2022 at 11:59p.m. PT , at the AAIC website. Learn more about Dr. Percy Griffin at his bio on the Alzheimer's Association website. Listen to our AAIC special series episode with Dr. Carl Hill, mentioned by Dr. Chin at 3:41, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen. Listen to our AAIC special series episode with Dr. Heather Snyder, mentioned by Dr. Chin at 18:22, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen Find the news highlights on diet, racism, preeclampsia, COVID-19, and more mentioned by Dr. Chin at the AAIC website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

Coverage from the Alzheimer's Association International Conference (AAIC) bringing together early career researchers to share their conference highlights. In the last of this weeks special shows, Dr Natasha Clarke from Centre de recherche de l'Institut universitaire de gériatrie de Montréal chairs the discussion with Dr Richard Lofthouse from University of Aberdeen, Dr Diana Karamacoska from Western Sydney University and Anqesha Murray, at Rensselaer Polytechnic Institute, New York. Sharing highlights from the third day of the world's largest dementia conference. Follow the conference live at #AAIC22 You can find out more about our panellists, and their work on our website. There you will also find a full transcript: www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

Coverage from the Alzheimer's Association International Conference (AAIC) bringing together early career researchers to share their conference highlights. In today's show, Dr Sarah Bauermeister from University of Oxford hosts, with guests Dr Claire Lancaster from University of Sussex, Esther Hui from University College London and and Dr Darina Petrovsky, Rutgers University Sharing highlights from the third day of the world's largest dementia conference. Follow the conference live at #AAIC22 You can find out more about our panellists, and their work on our website. There you will also find a full transcript: www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

Coverage from the Alzheimer's Association International Conference (AAIC) bringing together four attendees to chat over coffee, and share their highlights. In todays show, we welcome back Dr Isabel Castanho to take her first turn in the hosts chair, with special guests and show newcomers Dr Annalise Rahman-Filipiak from University of Michigan, Dr Connor Richardson from Newcastle University and Dr Bhargav Teja Nallapu from Albert Einstein College of Medicine. Sharing highlights from the second day of the worlds largest dementia conference. Follow the conference live at #AAIC22 You can find out more about our panellists, and their work on our website. There you will also find a full transcript: https://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

For the first time since 2019, we're back at the Alzheimer's Association International Conference (AAIC) in-person – which means we can bring together attendees to chat over coffee, and share their highlights. In todays show, long-time listener and contributor, Sarah Gregory from the University of Edinburgh is our guest host, talking with Dr Ríona McArdle, from Newcastle University, Dr Lillian Hung from University of British Columbia and Dr Sarah-Naomi James from University College London. Sharing highlights from the Tech and Dementia Preconference session and the first day, with a focus on equality, diversity and inclusion, and co-production. Follow the conference live at #AAIC22 You can find out more about our panellists, and their work on our website. There you will also find a full transcript: www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

AAIC Special Series Part 7: Recent studies have shown that 1 in 5 U.S. adults who were diagnosed with COVID-19 now deal with Long COVID, a condition where individuals report fatigue, cognitive issues, difficulty breathing, and other symptoms lasting at least three months after infection. With these reported effects on cognition and brain health, what else do we know about COVID's impact on the brain? Dr. Heather Snyder joins us to talk about what we know about COVID-19's effects on the brain and her upcoming scientific session at AAIC 2022. Guest: Heather Snyder, PhD, vice president, medical & scientific relations, Alzheimer's Association Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Read more about Dr. Snyder at her bio on the Alzheimer's Association website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 6: Dr. Krista Lanctôt joins the podcast to discuss apathy, how it develops in people with Alzheimer's disease, and her upcoming AAIC 2022 plenary talk. Guest: Krista Lanctôt, PhD, senior scientist, Sunnybrook Health Sciences Centre, full professor, University of Toronto Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Lanctot at her bio on the University of Toronto website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 5: Bringing together scientists, clinicians, and research participants from all over the world, AAIC 2022 showcases the work and experiences of people from unique backgrounds and perspectives and highlights the importance of diversity in Alzheimer's disease research. Dr. Carl Hill joins the podcast to discuss why diversity is important in scientific research and how AAIC 2022 supports efforts to make Alzheimer's disease research more equitable and inclusive. Guest: Carl Hill, PhD, MPH, chief diversity, equity and inclusion officer, Alzheimer's Association Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Listen to our past episode of Dementia Matters with Dr. Carl Hill on our website, Spotify, Apple Podcasts, YouTube, or wherever you get your podcasts.  Learn more about Dr. Carl Hill on the Alzheimer's Association website. Learn more about Henrietta Lacks' story (mentioned by Dr. Hill at 8:53) by checking out the Mind Readers Book Club discussion about the book, The Immortal Life of Henrietta Lacks, on our YouTube page. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 4: Research into delirium, a condition where older adults experience acute confusional states during hospitalizations, and its connections to dementia have led to  numerous advancements in hospital care and treatments. Dr. Sharon Inouye joins the podcast to discuss how our understanding of delirium has changed over the past 30 years and previews her upcoming AAIC plenary talk about the intersection of delirium and dementia. Guest: Sharon Inouye, PhD, director, Aging Brain Center, Hinda and Arthur Marcus Institute for Aging Research, professor, Harvard Medical School Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Inouye at her bio on the Marcus Institute for Aging Research website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 3: Mild cognitive impairment (MCI) is an early stage of memory loss and cognitive impairment that can develop into dementia. While physicians have medications they can prescribe to manage the condition, many researchers and doctors are focusing on lifestyle interventions that could support a person's cognition and address behavioral changes. Dr. Linda Lam joins the podcast to discuss her work studying mild cognitive impairment and preview her upcoming AAIC plenary talk on non-pharmacological treatments for MCI and dementia. Guest: Linda Lam, MBChB, MD, professor, Chinese University of Hong Kong Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Linda Lam on the Chinese University of Hong Kong website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 2: Attending scientific conferences is usually a major commitment, often requiring attendees to travel, pay attendance fees, and take time out during the day to learn about groundbreaking research. Recent conferences like the Alzheimer's Association International Conference (AAIC) are opening their doors virtually to make the events more accessible to research participants, care partners, and the general public. Sarah Walter joins the podcast as part of our special series previewing AAIC 2022 to discuss her article on how virtual scientific conferences impact research participant engagement and why it's important for participants to hear about the research they're involved in. Guest: Sarah Walter, MSc, program administrator, Alzheimer's Clinical Trials Consortium, Alzheimer's Therapeutic Research Institute, University of Southern California Show Notes AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Read Walter's article, “Can Virtual Scientific Conferences Facilitate Two-Way Learning between Dementia Researchers and Participants?” through the National Library of Medicine. Learn more about Sarah Walter on the Alzheimer's Clinical Trials Consortium website. Connect with us   Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

AAIC Special Series Part 1: To kick off our month-long special series previewing the 2022 Alzheimer's Association International Conference, or AAIC, we've invited  Claire Sexton, senior director of the Alzheimer's Association's scientific programs, to join us to discuss the goals of AAIC, how the pandemic impacted the influential conference, and what she's looking forward to at this year's event. Guest: Claire Sexton, DPhil, senior director of scientific programs and outreach, Alzheimer's Association Show Notes The AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Claire Sexton on the Alzheimer's Association website. Connect with us Find transcripts and more at our website. Email Dementia Matters at dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

In this weeks podcast, Adam Smith speaks with Alzheimer's Association Director, Scientific Programs and Outreach, Dr Claire Sexton. Discussing this years Alzheimer's Association International Conference (AAIC) July 31 - August 4 2022. Taking place in-person in San Diego, USA and online - the world's leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer's disease. Learn what the organisors have planned for this years event, new features and about some of the amazing sessions planned for those attending in-person and online. Students worldwide and researchers from Low and Middle Income Countries are now eligable for free ISTAART Membership (and ISTAART members can attend the AAIC Online for Free) - Become a member, then register for the conference if you can't make it in-person. To book your place visit - https://aaic.alz.org/ Join ISTAART to get a free online ticket - www.alz.org/istaart A transcript of this podcast is also available here https://www.dementiaresearcher.nihr.ac.uk/podcast-aaic-2022-preview/ Dr Claire Sexton Bio https://www.dementiaresearcher.nihr.ac.uk/profile-dr-claire-sexton/ Adam Smith Bio https://www.dementiaresearcher.nihr.ac.uk/podcast-profile-adam-smith/ _________________________ Finally, please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. Register on our website to receive your weekly bulletin, and to access more great content – blogs, science, career support + much more www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support.

There are plenty of drugs both legal and illegal that people use every day. For some it's a casual thing, for others it's a debilitating practice that consumes their thoughts. Drugs appear to be a gateway to escaping reality, but is it really that simple? Josh talks with a recovered ice addict, the head of an addiction lab, and revisits his own past to find out more. Dive deep into the rush... of drugs. If this episode has affected you in any way, you can call the National Alcohol and Other Drug Hotline for free and confidential advice about alcohol and other drugs on 1800 250 015, or chat online via The Alcohol & Drug Information Service (ADIS) Web Chat https://yourroom.health.nsw.gov.au/getting-help/Pages/ADIS-Web-Chat.aspx  LINKS Josh Szeps @joshszeps Nova Podcasts Instagram @novapodcastsofficial Prof Andrew Lawrence https://florey.edu.au/science-research/scientist-directory/professor-andrew-lawrence  Australian Anti Ice Campaign https://australianantiicecampaign.org.au/  Naitonal Support Line 1800 NO TO ICE (1800 66 86 423) CREDITS Host: Josh Szeps Managing Producer: Elle Beattie Producer: Amy Kimball Editor: Adrian Walton See omnystudio.com/listener for privacy information.

Hideki Garren, MD, PhD, Chief Medical Officer at Prothena discusses data from two presentations at the Alzheimer's Association International Conference (AAIC); PRX012, Prothena's next generation anti-amyloid beta (Aβ) antibody and the dual Aβ-tau vaccine being developed for the prevention and treatment of Alzheimer's Disease (AD). He talks about the company's approach to addressing the AD global healthcare crisis. #Alzheimer #AAIC H​ideki Garren, M.D., Ph.D.​, Chief Medical Officer​. Dr. Garren has served as our Chief Medical Officer since April 2021. Before joining Prothena, between 2013 and 2021 Dr. Garren was with F. Hoffmann-La Roche Ltd. (Roche) & Genentech Inc. and most recently served as Vice President, Global Head of Neuroimmunology with responsibility for leading Roche's Neuroimmunology franchise team. Prior to Roche, between 2011 and 2013, Dr. Garren held the role of Executive Director, Translational Medicine Expert in Neuroscience with Novartis Pharma. Dr. Garren also served as Co-Founder, Executive Vice President, Chief Scientific Officer, and Chief Operating Officer of Bayhill Therapeutics, Inc., a company he started in 2002 based on a technology platform he co-invented while at Stanford University. He currently serves on the board of directors of Coya Therapeutics, a privately-held clinical-stage biotechnology company. Dr. Garren earned his Bachelor of Science from the California Institute of Technology and his MD and PhD from the University of California, Los Angeles (UCLA). He completed his internship in internal medicine at UCLA, and his residency in neurology and fellowship in neuroimmunology at Stanford University.